Is Eli Lilly overextended? Or are investors still underestimating how big this GLP-1 story can get? Here’s the blunt answer: LLY isn’t cheap. But calling it a bubble is lazy. Let’s look at what’s actually happening. In 2025, Lilly pulled in $65.2B in revenue — up 45% year over year. More than half of that…